Latest Commercialisation News

FortifAI’s Nol8 FPGA appliance dramatically reduces AI infrastructure costs by replacing up to 60,000 CPUs, slashing annual operational expenses from millions to tens of thousands of dollars.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Victory Metals has unlocked a rare metallurgical feat at North Stanmore, achieving a globally top-tier 72% heavy rare earth ratio and unveiling a second revenue stream from zircon-hafnium concentrate using a low-cost gravity separation process.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

St George Mining has expanded its Araxá rare earths-niobium resource by 75% to 70.91Mt at 4.06% TREO, positioning the project among the world’s largest carbonatite deposits. The company also acquired land for processing facilities and forged new downstream partnerships, supported by Minas Gerais state tax incentives.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Resolution Minerals has successfully produced high-grade tungsten concentrates from historical stockpiles at its Golden Gate mine, achieving a 19-fold upgrade and strong recovery rates using simple gravity separation techniques.

European Resources has more than doubled its Korsnäs rare earth resource following a successful drilling program and metallurgical advances, underpinning a $3.4 million capital raise to fund further development.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

First Graphene has secured advanced graphene coatings technology through the AU$250,000 acquisition of Ionic Industries and Imagine Intelligent Materials, gaining immediate entry into lucrative geotextile and environmental infrastructure sectors.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.